tiprankstipranks
Trending News
More News >
Apollo Hospitals Enterprise Limited (IN:APOLLOHOSP)
:APOLLOHOSP
India Market
Advertisement

Apollo Hospitals Enterprise Limited (APOLLOHOSP) AI Stock Analysis

Compare
8 Followers

Top Page

IN:APOLLOHOSP

Apollo Hospitals Enterprise Limited

(APOLLOHOSP)

Select Model
Select Model
Select Model
Neutral 66 (OpenAI - 4o)
Rating:66Neutral
Price Target:
₹8,294.00
▲(12.76% Upside)
Apollo Hospitals' strong financial performance is the primary driver of its stock score, supported by robust revenue growth and efficient cash flow management. However, technical indicators suggest potential bearish trends, and the high P/E ratio indicates possible overvaluation, which tempers the overall score.

Apollo Hospitals Enterprise Limited (APOLLOHOSP) vs. iShares MSCI India ETF (INDA)

Apollo Hospitals Enterprise Limited Business Overview & Revenue Model

Company DescriptionApollo Hospitals Enterprise Limited, together with its subsidiaries, provides healthcare services in India and internationally. The company's healthcare facilities comprise primary, secondary, and tertiary care facilities. Its tertiary care hospitals provide advanced healthcare services; and specialties in cardiac sciences, oncology, neurosciences, orthopedics, emergency, robotic surgery, and transplants. The company also provides other services, such as project consultancy, health insurance, medical colleges, medvarsity for e-learning, and research services. In addition, it operates pharmacies, primary care clinics, birthing centers, specialized birthing centers, single specialty clinics, primary health centers and diagnostic chains, dental clinics, and daycare and home healthcare centers. The company's footprint includes 9,911 beds, 4,529 pharmacies, and 1,734 national retail healthcare centers, as well as Apollo 24/7, an end-to-end omni-channel healthcare platform and www.apollopharmacy, an online pharmacy. Apollo Hospitals Enterprise Limited was incorporated in 1979 and is based in Chennai, India.
How the Company Makes MoneyApollo Hospitals generates revenue primarily through its hospital operations, which include inpatient and outpatient services. The company charges fees for various medical services, surgeries, and treatments provided in its hospitals. Additionally, Apollo earns significant income from its diagnostic services, including laboratory tests and imaging services. The retail pharmacy segment contributes to revenue by selling prescription and over-the-counter medications, health products, and wellness services. Strategic partnerships with insurance companies and health plans also enhance revenue through reimbursements for services rendered. Furthermore, Apollo has ventured into digital health initiatives, which provide an additional revenue stream through telemedicine and online consultations.

Apollo Hospitals Enterprise Limited Financial Statement Overview

Summary
Apollo Hospitals demonstrates strong financial performance with robust revenue growth, improved profitability, and efficient cash flow management. The balance sheet is stable, though maintaining control over debt levels is important for future stability.
Income Statement
85
Very Positive
Apollo Hospitals shows strong revenue growth with a significant increase in total revenue over the past year. The gross profit margin is healthy, indicating efficient cost management. The net profit margin has improved, demonstrating increased profitability. Both EBIT and EBITDA margins are robust, reflecting effective operations and earnings before interest, taxes, depreciation, and amortization.
Balance Sheet
78
Positive
The company's balance sheet reflects a stable financial position with a reasonable debt-to-equity ratio, suggesting manageable leverage. The equity ratio indicates a strong capital structure. The return on equity shows good profitability from shareholders' investments, though there is room for improvement.
Cash Flow
80
Positive
Apollo Hospitals maintains strong operating cash flow, which covers net income well, indicating efficient cash conversion. The free cash flow growth rate is commendable, although the capital expenditures have increased, impacting free cash flow. The company shows effective cash management to support operations and future investments.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue225.50B217.94B190.59B166.13B146.63B105.60B
Gross Profit76.27B73.50B63.98B56.68B51.31B31.40B
EBITDA29.83B27.98B22.11B19.11B20.45B9.75B
Net Income15.90B14.46B8.99B8.19B10.56B1.50B
Balance Sheet
Total Assets0.00206.57B167.53B144.28B131.92B114.17B
Cash, Cash Equivalents and Short-Term Investments20.10B27.93B11.89B7.26B10.48B14.23B
Total Debt0.0078.64B53.33B43.32B40.68B41.60B
Total Liabilities-86.53B120.05B94.33B78.96B73.15B66.14B
Stockholders Equity86.53B82.12B69.35B61.97B56.23B46.02B
Cash Flow
Free Cash Flow0.002.16B7.83B2.49B9.71B9.78B
Operating Cash Flow0.0019.29B19.20B13.77B16.28B12.73B
Investing Cash Flow0.00-34.77B-15.37B-8.71B-8.47B-8.72B
Financing Cash Flow0.0016.21B-3.11B-6.33B-7.93B-3.40B

Apollo Hospitals Enterprise Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price7355.45
Price Trends
50DMA
7671.29
Negative
100DMA
7601.29
Negative
200DMA
7171.31
Positive
Market Momentum
MACD
-104.42
Positive
RSI
33.23
Neutral
STOCH
13.08
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:APOLLOHOSP, the sentiment is Negative. The current price of 7355.45 is below the 20-day moving average (MA) of 7574.65, below the 50-day MA of 7671.29, and above the 200-day MA of 7171.31, indicating a neutral trend. The MACD of -104.42 indicates Positive momentum. The RSI at 33.23 is Neutral, neither overbought nor oversold. The STOCH value of 13.08 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:APOLLOHOSP.

Apollo Hospitals Enterprise Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
71
Outperform
₹403.95B47.570.23%14.72%8.37%
66
Neutral
₹1.12T71.400.26%13.66%41.32%
66
Neutral
₹1.12T82.780.13%32.17%28.12%
65
Neutral
₹335.69B62.800.04%15.78%15.01%
61
Neutral
₹769.00B88.540.11%15.33%54.62%
61
Neutral
₹105.27B68.820.21%15.41%5.93%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:APOLLOHOSP
Apollo Hospitals Enterprise Limited
7,329.20
274.82
3.90%
IN:FORTIS
Fortis Healthcare Ltd.
920.15
256.33
38.61%
IN:MAXHEALTH
Max Healthcare Institute Ltd
1,157.15
172.14
17.48%
IN:MEDANTA
Global Health Limited
1,250.95
148.75
13.50%
IN:METROPOLIS
Metropolis Healthcare Ltd.
1,951.35
-200.35
-9.31%
IN:NH
Narayana Hrudayalaya Ltd.
1,956.90
694.52
55.02%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 01, 2025